Search results
Results from the WOW.Com Content Network
Following is a list of antipsychotics, sorted by class. Antipsychotics. Antipsychotics by class Generic name Brand names Chemical class ATC code
Use during pregnancy is of unclear safety. [13] [14] Lurasidone was first approved for medical use in the United States in 2010. [2] In 2013, it was approved in Canada and by the U.S. Food and Drug Administration (FDA) to treat bipolar depression, either as monotherapy or adjunctively with lithium or valproate.
In September 2024, it was approved for medical use in the United States. [1] [2] It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. [2] [3]
Saphris – atypical antipsychotic used to treat schizophrenia and bipolar disorder; Serax – anti-anxiety medication of the benzodiazepine class, often used to help during detoxification from alcohol or other addictive substances; Serentil (mesoridazine) – an antipsychotic drug used in the treatment of schizophrenia [1]
Quetiapine was developed in 1985 and was approved for medical use in the United States in 1997. [4] [11] [14] It is available as a generic medication. [15] In 2022, it was the most prescribed antipsychotic and 82nd most commonly prescribed medication in the United States, with more than 8 million prescriptions.
The deal was unanimously approved by both companies' boards of directors. Karuna's top asset is KarXT, an experimental antipsychotic with a promising novel mechanism.
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
Shares of the California-based company fell 16% in extended trading. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the ...